7th Annual Interdisciplinary Prostate Cancer Congress
7th Annual Interdisciplinary Prostate Cancer Congress™
The 7th Annual Interdisciplinary Prostate Cancer Congress
™ is a one-day educational meeting that brings together the top experts from key specialties involved in the care of patients with prostate cancer to discuss state-of-the-art treatments and current guidelines, debate controversies and clinical challenges, and review recent trial data and emerging therapeutic approaches with the potential to impact clinical practice.
Today, the interdisciplinary care of prostate cancer has become a reality, and urologists along with radiation, surgical, and medical oncologists are all involved in the management of these patients. In order to provide optimal care, it is essential that all members of the treatment team stay up-to-date on current trends and emerging data, not just in their own area, but also in the related specialties. The Interdisciplinary Prostate Cancer Congress
provides an opportunity for clinicians to receive concise didactic updates on best practices and investigational strategies in each of these topical areas, accompanied by practical case discussions moderated by an expert panel in a multidisciplinary tumor board–like environment.
This educational activity is directed toward medical oncologists, radiation oncologists, surgeons, and urologists involved in the treatment and management of patients with prostate cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals interested in the treatment of prostate cancer may also participate.
At the conclusion of this symposium, you should be better prepared to:
Evaluate emerging clinical data regarding new agents and evolving strategies for the treatment of prostate cancer
Summarize recent risk-assessment strategies for patients with newly diagnosed prostate cancer
Compare efficacy and safety data supporting various management options for localized prostate cancer, including radical prostatectomy, radiation therapy, brachytherapy, hormonal therapy, and active surveillance
Discuss clinical data describing patient populations with localized disease that appear to benefit from early treatment
Discuss evidence supporting several different treatment options for patients with advanced prostate cancer, including secondary hormonal therapy, chemotherapy, immunotherapy, and radioisotope therapy
Assess patients with prostate cancer for eligibility on promising clinical trials
Faculty and Staff Disclosures
The following individuals have no relevant financial relationships with commercial interests to disclose: Peter B. Schiff, MD, PhD, FASTRO.
The staff of Physicians’ Education Resource®
, LLC: Wendy C. Ashmen; Dru Dace, PhD; and Ann C. Lichti, CCMEP.
The following individuals have relevant financial relationships with commercial interests to disclose:
E. David Crawford, MD
— Consultant: Dendreon Corporation, Ferring Pharmaceuticals Inc., Janssen Pharmaceuticals, MDxHealth. Spousal employment relationship with Ferring Pharmaceuticals (role not relevant to the content for which Dr. Crawford is responsible); Robert Dreicer, MD, MS, FACP, FASCO
— Grant/Research Support: BIND Therapeutics, Inc., Dendreon Corporation, Exelixis, Inc., Progenics Pharmaceuticals, Inc.; Consultant: Bayer Corporation, Janssen Pharmaceuticals, Medivation, Inc., Millennium Pharmaceuticals, Inc.; Leonard G. Gomella, MD, FACS
— Grant/Research Support: Dendreon Corporation, Janssen Pharmaceuticals; Consultant: Astellas Pharma US, Inc., Bayer Corporation, Dendreon Corporation, Janssen Pharmaceuticals; Daniel P. Petrylak, MD
— Grant/Research Support – OncoGeneX Pharmaceuticals Inc., Progenics Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Millennium Pharmaceuticals, Inc., Celgene Corporation, Dendreon Corporation; Consultant: Bayer Corporation, Bellicum Pharmaceuticals, Inc., Dendreon Corporation, Exelixis, Inc., Ferring Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Medivation, Inc., Millennium Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Pfizer Inc.; A. Oliver Sartor, MD
— Consultant: Algeta ASA, Aragon Pharmaceuticals, Astellas Pharma US, Inc., Bavarian Nordic, Inc., Bayer Corporation, Bellicum Pharmaceuticals, Inc., Dendreon Corporation, Johnson & Johnson Services, Inc., Medivation, Inc., OncoGeneX Pharmaceuticals Inc., Pfizer Inc., sanofi-aventis U.S. LLC; Grant/Research Support: Algeta ASA, Bayer Corporation, Johnson & Johnson Services, Inc., sanofi-aventis U.S. LLC, Takeda Pharmaceutical Company Limited.
Off-label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®
, LLC or any of the companies that provided commercial support for this activity.